Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 509 of the 513 references it cites were found in a registry or an index; 127 of the 249 sources its claims cite were checked for support.

Drug repurposing for cancer therapy

Open access
Xia, Ying, Sun, Ming, Huang, Hai, Jin, Wei-Lin · 2024 · Signal Transduction and Targeted Therapy

Abstract

Comprehensive review of methods and candidate repurposed drugs for cancer therapy.

Overview

CoChat Summary

## TL;DR

This is a narrative review of drug repurposing for cancer therapy, summarizing experimental and computational strategies, hallmark-targeting examples, tumor microenvironment targets, and nanomaterial-based delivery. It argues that repurposed drugs may speed development and reduce cost, but clinical translation remains limited by bioavailability, dosing, toxicity, and regulatory barriers.

## Key findings

  • The review organizes drug repurposing around the 14 hallmarks of cancer and the tumor microenvironment (TME), and notes that repurposed drugs may target multiple malignancy features and support combination therapy.
  • It states that conventional drug development can take 10–15 years and cost $1–2 billion, whereas repurposing is faster and cheaper because existing drugs already have known safety, dosage, and toxicity profiles.
  • The paper highlights several reported quantitative findings from prior studies, including a 45% risk reduction in thyroid cancer among metformin users in Eastern countries, and lower gynecological cancer occurrence with metformin: HR = 0.60 (95% CI: 0.49–0.74), endometrial cancer HR = 0.65 (95% CI: 0.50–0.85), and ovarian cancer HR = 0.47 (95% CI: 0.27–0.82).
  • It also cites a phase I clinical trial of leflunomide in refractory multiple myeloma where disease stabilization occurred in 9 of 11 patients.

## Methods

  • Design: Narrative review/systematic overview of published work on drug repurposing for cancer therapy, centered on hallmarks of cancer, TME-targeting therapy, and nanomaterial-based delivery.
  • Data/sample: The text does not report a primary study sample; instead, it synthesizes examples from preclinical studies, epidemiological analyses, and clinical trials, and mentions use of databases and tables of repurposed-drug candidates.
  • Main analysis: The paper categorizes repurposing strategies into experimental approaches (including phenotypic screening and organoid/tumoroid models) and computational approaches (including molecular docking, network analysis, data mining, similarity analysis, machine learning, and transcriptional signature methods).

## Limitations

  • The paper explicitly states that many repurposed drugs have not yet translated into clinical application, and that clinical trial evidence is limited for several TME-targeting candidates.
  • It notes several practical barriers: bioavailability limits, instability, poor solubility, toxicity, dosing uncertainty, patent/IP issues, regulatory barriers, and limited funding for trials.
  • The text also makes evident, but does not present as a formal limitation, that much of the evidence discussed is preclinical and often based on small or ongoing clinical studies rather than large randomized trials.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41392-024-01808-1

Cites

509 of 509 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Tumoroids model in drug repurposing. a Schematic showing the generation of patient-derived organoids (PDOs) from a cancer biopsy: enzymatic digestion, embedding in extracellular matrix, addition of growth medium and cancer tumoroids enrichment by media compound withdrawal and/or addition of mutation related inhibitors. b, c The tumoroid model is used to screen drug repurposing candidates, resulting in the identification of drugs for preclinical and clinical testing. This figure was created with Biorender.com
Fig. 1 Tumoroids model in drug repurposing. a Schematic showing the generation of patient-derived organoids (PDOs) from a cancer biopsy: enzymatic digestion, embedding in extracellular matrix, addition of growth medium and cancer tumoroids enrichment by media compound withdrawal and/or addition of mutation related inhibitors. b, c The tumoroid model is used to screen drug repurposing candidates, resulting in the identification of drugs for preclinical and clinical testing. This figure was created with Biorender.comCC BY · PubMed Central
Fig. 2 Diverse cancer hallmarks targeted by repurposed non-oncology drugs. Repurposed non-oncology candidates have shown great promise against cancer by targeting different hallmarks of cancer including sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, activating invasion and metastasis, genome instability and mutation, tumor-promoting inflammation, reprogramming energy metabolism, evading immune destruction, unlocking phenotypic plasticity, non-mutational epigenetic regulation, polymorphic microbiomes, and senescent cells. This figure was created with Biorender.com
Fig. 2 Diverse cancer hallmarks targeted by repurposed non-oncology drugs. Repurposed non-oncology candidates have shown great promise against cancer by targeting different hallmarks of cancer including sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, activating invasion and metastasis, genome instability and mutation, tumor-promoting inflammation, reprogramming energy metabolism, evading immune destruction, unlocking phenotypic plasticity, non-mutational epigenetic regulation, polymorphic microbiomes, and senescent cells. This figure was created with Biorender.comCC BY · PubMed Central
Fig. 3 Inducing cell death in cancers by repurposed non-oncology drugs. Regulated cell death (RCD) is a critical and active process that is controlled by specific signal transduction pathways and can be regulated by drug interventions. Repurposed non-oncology candidates can exert anticancer effects by inducing classical apoptosis and other RCD processes, such as ferroptosis, autophagy, necroptosis and pyroptosis. This figure was created with Biorender.com
Fig. 3 Inducing cell death in cancers by repurposed non-oncology drugs. Regulated cell death (RCD) is a critical and active process that is controlled by specific signal transduction pathways and can be regulated by drug interventions. Repurposed non-oncology candidates can exert anticancer effects by inducing classical apoptosis and other RCD processes, such as ferroptosis, autophagy, necroptosis and pyroptosis. This figure was created with Biorender.comCC BY · PubMed Central
Fig. 4 Classification of the tumor microenvironment. Underlying mechanisms of repurposed drugs targeting the specialized tumor microenvironments (TMEs). The TME can be divided into seven specialized microenvironments: hypoxic niche, immune microenvironment, metabolic microenvironment, acidic niche, innervated niche, mechanical microenvironment, and microbial microenvironment. Repurposed drugs with multi-targeted effects may reverse the effects of tumor-promoting microenvironments. TAM tumor-associated macrophage, CAF cancer-associated fibroblast, MDSC myeloid-derived suppressor cell, PNI perineural invasion, NK natural killer. This figure was created with Biorender.com
Fig. 4 Classification of the tumor microenvironment. Underlying mechanisms of repurposed drugs targeting the specialized tumor microenvironments (TMEs). The TME can be divided into seven specialized microenvironments: hypoxic niche, immune microenvironment, metabolic microenvironment, acidic niche, innervated niche, mechanical microenvironment, and microbial microenvironment. Repurposed drugs with multi-targeted effects may reverse the effects of tumor-promoting microenvironments. TAM tumor-associated macrophage, CAF cancer-associated fibroblast, MDSC myeloid-derived suppressor cell, PNI perineural invasion, NK natural killer. This figure was created with Biorender.comCC BY · PubMed Central
Fig. 5 Nanocarriers in repurposed drug delivery in cancer. Multiple nanocarriers including polymeric nanocarriers, mesoporous silica nanoparticles, polymeric micelles, liposomes, and metallic nanoparticles have shown promising effects in the delivery of repurposed therapeutics in cancer. Targeted cancer NP drug delivery systems: a Diversity of NPs in thedrug delivery platform. b Active-targeting ligand-decorated repurposed drug-loaded NPs for cancers. c Passive tumor targeting via the enhanced permeability and retention (EPR) effect. d Internalization of active-targeting NPs driven by receptor activation. This figure was created with Biorender.com
Fig. 5 Nanocarriers in repurposed drug delivery in cancer. Multiple nanocarriers including polymeric nanocarriers, mesoporous silica nanoparticles, polymeric micelles, liposomes, and metallic nanoparticles have shown promising effects in the delivery of repurposed therapeutics in cancer. Targeted cancer NP drug delivery systems: a Diversity of NPs in thedrug delivery platform. b Active-targeting ligand-decorated repurposed drug-loaded NPs for cancers. c Passive tumor targeting via the enhanced permeability and retention (EPR) effect. d Internalization of active-targeting NPs driven by receptor activation. This figure was created with Biorender.comCC BY · PubMed Central

Verification

Claims the paper makes

99 Valid · 15 Not valid · 82 Not checked · 27 Own results and interpretations

113 more claims · 51 with their cited sources checked

Create a free account to see all 223 claims and to verify the 13 references still open.

See all claims — free account
  • It may state two separate claims as one. 87
  • Probably not a substantial claim. 25

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 513 references

Cited by

See all 443

Metadata

Authors
Xia, Y., Sun, M., Huang, H., & Jin, W.-L.
Affiliations
  • Johns Hopkins University (US)
  • Guiyang Medical University (CN)
Corresponding author
Huang, Hai
Venue
Signal Transduction and Targeted Therapy
Published
2024-04-19
Volume
9
Issue
1
Pages
92-92
ISSN
2059-3635 (ISSN-L)
OpenAlex
W4394934376
Cited by
443
References
513
Citations by year
2026: 168 · 2025: 214 · 2024: 60
FWCI
12.35
Type
journal article
Language
en
Open access
Licence
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (82060442)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
drug repurposing, cancer therapy, cancer hallmarks, tumor microenvironment, drug resistance, combination therapy, nanotechnology, topical drug delivery, anticancer agents, clinical translation
MeSH terms
Combined Modality Therapy, Humans, Neoplasms, Drug Delivery Systems, Treatment Outcome, Drug Repositioning, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Drug repurposing for cancer therapy. https://app.cochat.ai/papers/10.1038/s41392-024-01808-1
The paper
Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024). Drug repurposing for cancer therapy. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-024-01808-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.